Lung Diseases  >>  budesonide (MAP0010)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
budesonide (MAP0010) / AbbVie
NCT00995904: Tolerability and PK of Submicron Budesonide in Children 4 to 11 Years Old With Mild-To-Moderate Stable Asthma

Completed
2
25
US
84ug MAP0020, 42ug MAP0020, 21ug MAP0020
Allergan, MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
Asthma
11/09
11/09

Download Options